Immunome vs Traws Pharma
IMNM and TRAW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMNM and TRAW compare
Immunome is the larger company, worth 553 times as much as Traws Pharma ($2.1B against $3.9M).
Immunome scores higher on the StockData Score (6 against 5 for Traws Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMNM | TRAW |
|---|---|---|
| Size and price | ||
| Market cap | $2.1B | $3.9M |
| Share price | $18.77 | $0.251 |
| Change, 1 year | 7.7% | −88.3% |
| Change, 5 years | 9.1% | −99.7% |
| Beta (5Y) | 1.74 | 1.19 |
| Employees | 177 | 7 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 531× | – |
| P/B | 4.7× | – |
| FCF yield | −9.6% | – |
| Growth | ||
| Revenue growth (TTM) | −63.3% | – |
| Revenue growth, 5Y average | – | 64.6% |
| Profitability | ||
| Operating margin | −5948% | – |
| Net margin | −5594% | – |
| FCF margin | −5119% | – |
| Return on equity | −62.5% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 11.66 (better) | 0.93 |
| Altman Z-score | 21.85 (better) | −85.39 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −109% |
| Shareholder yield | 0.00% (better) | −109% |
| Ownership | ||
| Held by institutions | 104% | 40.1% |
| Held by insiders | 6.4% | 35.7% |
| Insider net buying, 12 months | −$25.2M | $998K (better) |
| Short interest, % of float | 15.2% | 6.9% |
Go deeper
- IMNM stock overview
- IMNM income statement
- IMNM valuation and score
- TRAW stock overview
- TRAW income statement
- TRAW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.